Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015 (2015), Article ID 595363, 6 pages
http://dx.doi.org/10.1155/2015/595363
Review Article

Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination

1Research Center for Immunotherapy (FZI), Langenbeckstr. 1, Building 708, 55131 Mainz, Germany
2Biopharmaceutical New Technologies (BioNTech) Corporation, An der Goldgrube 12, 55131 Mainz, Germany
3TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University, Freiligrathstr. 12, 55131 Mainz, Germany

Received 23 September 2015; Accepted 15 December 2015

Academic Editor: Steve Pascolo

Copyright © 2015 Mathias Vormehr et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. B. Alexandrov, S. Nik-Zainal, D. C. Wedge, S. A. J. R. Aparicio, S. Behjati, A. V. Biankin et al., “Signatures of mutational processes in human cancer,” Nature, vol. 500, no. 7463, pp. 415–421, 2013. View at Publisher · View at Google Scholar
  2. T. Boon and O. Kellermann, “Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line,” Proceedings of the National Academy of Sciences of the United States of America, vol. 74, no. 1, pp. 272–275, 1977. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Lurquin, A. Van Pel, B. Mariamé et al., “Structure of the gene of tum-transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells,” Cell, vol. 58, no. 2, pp. 293–303, 1989. View at Publisher · View at Google Scholar · View at Scopus
  4. NHGRI, Human Genome Project Completion: Frequently Asked Questions, 2010, http://www.genome.gov/11006943.
  5. E. C. Hayden, “Technology: the $1,000 genome,” Nature, vol. 507, no. 7492, pp. 294–295, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. J. C. Castle, S. Kreiter, J. Diekmann et al., “Exploiting the mutanome for tumor vaccination,” Cancer Research, vol. 72, no. 5, pp. 1081–1091, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. C. M. Britten, H. Singh-Jasuja, B. Flamion et al., “The regulatory landscape for actively personalized cancer immunotherapies,” Nature Biotechnology, vol. 31, no. 10, pp. 880–882, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Duan, J. Duitama, S. Al Seesi et al., “Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity,” The Journal of Experimental Medicine, vol. 211, no. 11, pp. 2231–2248, 2014. View at Publisher · View at Google Scholar
  9. M. Yadav, S. Jhunjhunwala, Q. T. Phung et al., “Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing,” Nature, vol. 515, no. 7528, pp. 572–576, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. S. P. Haen and H.-G. Rammensee, “The repertoire of human tumor-associated epitopes—identification and selection of antigens and their application in clinical trials,” Current Opinion in Immunology, vol. 25, no. 2, pp. 277–283, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. M. M. Gubin, X. Zhang, H. Schuster et al., “Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens,” Nature, vol. 515, no. 7528, pp. 577–581, 2014. View at Publisher · View at Google Scholar
  12. S. D. Brown, R. L. Warren, E. A. Gibb et al., “Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival,” Genome Research, vol. 24, no. 5, pp. 743–750, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Snyder, V. Makarov, T. Merghoub et al., “Genetic basis for clinical response to CTLA-4 blockade in melanoma,” The New England Journal of Medicine, vol. 371, no. 23, pp. 2189–2199, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. N. A. Rizvi, M. D. Hellmann, A. Snyder et al., “Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer,” Science, vol. 348, no. 6230, pp. 124–128, 2015. View at Publisher · View at Google Scholar
  15. E. Tran, S. Turcotte, A. Gros et al., “Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer,” Science, vol. 344, no. 6184, pp. 641–645, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Löwer, B. Y. Renard, J. de Graaf et al., “Confidence-based somatic mutation evaluation and prioritization,” PLoS Computational Biology, vol. 8, no. 9, Article ID e1002714, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Nothnagel, A. Herrmann, A. Wolf et al., “Technology-specific error signatures in the 1000 Genomes Project data,” Human Genetics, vol. 130, no. 4, pp. 505–516, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. A. Taub, H. C. Bravo, and R. A. Irizarry, “Overcoming bias and systematic errors in next generation sequencing data,” Genome Medicine, vol. 2, no. 12, article 87, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Kreiter, M. Vormehr, N. van de Roemer et al., “Mutant MHC class II epitopes drive therapeutic immune responses to cancer,” Nature, vol. 520, no. 7549, pp. 692–696, 2015. View at Publisher · View at Google Scholar
  20. T. Schumacher, L. Bunse, S. Pusch et al., “A vaccine targeting mutant IDH1 induces antitumour immunity,” Nature, vol. 512, no. 7514, pp. 324–327, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. P. F. Robbins, Y.-C. Lu, M. El-Gamil et al., “Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells,” Nature Medicine, vol. 19, no. 6, pp. 747–752, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. B. M. Carreno, V. Magrini, M. Becker-Hapak et al., “A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells,” Science, vol. 348, no. 6236, pp. 803–808, 2015. View at Publisher · View at Google Scholar
  23. N. Van Rooij, M. M. Van Buuren, D. Philips et al., “Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma,” Journal of Clinical Oncology, vol. 31, no. 32, pp. e439–e442, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Qin and T. Blankenstein, “CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells,” Immunity, vol. 12, no. 6, pp. 677–686, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. A. L. Bouwer, S. C. Saunderson, F. J. Caldwell et al., “NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge,” The Journal of Immunology, vol. 192, no. 5, pp. 2514–2521, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. S. P. Schoenberger, R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief, “T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions,” Nature, vol. 393, pp. 480–483, 1998. View at Publisher · View at Google Scholar
  27. B. Weide, S. Pascolo, B. Scheel et al., “Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients,” Journal of Immunotherapy, vol. 32, no. 5, pp. 498–507, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. S. M. Rittig, M. Haentschel, K. J. Weimer et al., “Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients,” Molecular Therapy, vol. 19, no. 5, pp. 990–999, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Heiser, D. Coleman, J. Dannull et al., “Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors,” Journal of Clinical Investigation, vol. 109, no. 3, pp. 409–417, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Holtkamp, S. Kreiter, A. Selmi et al., “Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells,” Blood, vol. 108, no. 13, pp. 4009–4017, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. A. N. Kuhn, M. Diken, S. Kreiter et al., “Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo,” Gene Therapy, vol. 17, no. 8, pp. 961–971, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Kreiter, A. Selmi, M. Diken et al., “Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals,” The Journal of Immunology, vol. 180, no. 1, pp. 309–318, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. U. Sahin, K. Karikó, and Ö. Türeci, “mRNA-based therapeutics—developing a new class of drugs,” Nature Reviews Drug Discovery, vol. 13, no. 10, pp. 759–780, 2014. View at Publisher · View at Google Scholar
  34. M. Hubo, B. Trinschek, F. Kryczanowsky, A. Tuettenberg, K. Steinbrink, and H. Jonuleit, “Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells,” Frontiers in Immunology, vol. 4, article 82, 14 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Kreiter, A. Selmi, M. Diken et al., “Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity,” Cancer Research, vol. 70, no. 22, pp. 9031–9040, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Diken, S. Kreiter, A. Selmi et al., “Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation,” Gene Therapy, vol. 18, no. 7, pp. 702–708, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. R. D. Granstein, W. Ding, and H. Ozawa, “Induction of anti-tumor immunity with epidermal cells pulsed with tumor—derived RNA or intradermal administration of RNA,” Journal of Investigative Dermatology, vol. 114, no. 4, pp. 632–636, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. J. A. Wolff, R. W. Malone, P. Williams et al., “Direct gene transfer into mouse muscle in vivo,” Science, vol. 247, no. 4949, pp. 1465–1468, 1990. View at Publisher · View at Google Scholar · View at Scopus
  39. J. S. Blum, P. A. Wearsch, and P. Cresswell, “Pathways of antigen processing,” Annual Review of Immunology, vol. 31, no. 1, pp. 443–473, 2013. View at Publisher · View at Google Scholar
  40. C. Linnemann, M. M. van Buuren, L. Bies et al., “High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma,” Nature Medicine, vol. 21, pp. 81–85, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Janetzki, C. M. Britten, M. Kalos et al., “‘MIATA’-minimal information about T cell assays,” Immunity, vol. 31, no. 4, pp. 527–528, 2009. View at Publisher · View at Google Scholar · View at Scopus